Reaction Details | |||
---|---|---|---|
Report a problem with these data | |||
Target | Mu-type opioid receptor | ||
Ligand | BDBM50122523 | ||
Substrate/Competitor | n/a | ||
Meas. Tech. | ChEMBL_145593 (CHEMBL749738) | ||
IC50 | 8±n/a nM | ||
Citation | Hanessian, S; Parthasarathy, S; Mauduit, M; Payza, K The power of visual imagery in drug design. Isopavines as a new class of morphinomimetics and their human opioid receptor binding activity. J Med Chem46:34-48 (2002) [PubMed] Article | ||
More Info.: | Get all data from this article, Assay Method | ||
Mu-type opioid receptor | |||
Name: | Mu-type opioid receptor | ||
Synonyms: | M-OR-1 | MOP | MOR-1 | MOR1 | MUOR1 | Mu Opioid Receptor | Mu opiate receptor | OPIATE Mu | OPRM1 | OPRM_HUMAN | hMOP | mu-type opioid receptor isoform MOR-1 | ||
Type: | G Protein-Coupled Receptor (GPCR) | ||
Mol. Mass.: | 44789.51 | ||
Organism: | Homo sapiens (Human) | ||
Description: | P35372 | ||
Residue: | 400 | ||
Sequence: |
| ||
BDBM50122523 | |||
n/a | |||
Name | BDBM50122523 | ||
Synonyms: | 4N,13N-dibenzyl-16,17-dimethyl-17-azatetracyclo[7.6.2.02,7.010,15]heptadeca-2(7),3,5,12,14-pentaene-4,13-diamine | ||
Type | Small organic molecule | ||
Emp. Form. | C32H35N3 | ||
Mol. Mass. | 461.6404 | ||
SMILES | C[C@@H]1[C@@H]2C3=CC(CC[C@H]3[C@H](Cc3ccc(NCc4ccccc4)cc23)N1C)=NCc1ccccc1 |w:27.32,wU:2.2,9.28,8.8,1.0,t:3,TLB:0:1:3.8:24.11.10,23:24:25.1:3.8,THB:26:25:3.8:24.11.10,7:8:25.1:24.11.10,12:11:25.1:3.8,(11.14,-2.39,;10.05,-3.49,;6.2,-2.23,;6.2,-.68,;6.2,.88,;7.54,1.65,;8.88,.88,;8.88,-.68,;7.54,-1.45,;7.76,-5.32,;6.2,-5.32,;4.87,-4.54,;3.54,-5.32,;2.21,-4.54,;2.21,-3,;.85,-2.21,;-.49,-2.97,;-.49,-4.51,;-1.84,-5.27,;-1.84,-6.8,;-.51,-7.58,;.83,-6.8,;.83,-5.27,;3.54,-2.23,;4.87,-3,;9.2,-4.77,;10.16,-5.97,;7.54,3.2,;6.2,3.97,;4.87,3.2,;4.87,1.68,;3.56,.91,;2.23,1.68,;2.23,3.2,;3.55,3.97,)| | ||
Structure |